N,N,5-三甲基-1,2-恶唑-3-甲酰胺 | 74531-16-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N,N,5-三甲基-1,2-恶唑-3-甲酰胺
• 中文别名: 3-异噻唑甲酰胺,N,N,5-三甲基-
• 英文名称: 5-methyl-isoxazole-3-carboxylic acid dimethylamide
• 英文别名: 5-Methyl-isoxazol-3-carbonsaeure-dimethylamid；N,N,5-Trimethylisoxazole-3-carboxamide；N,N,5-trimethyl-1,2-oxazole-3-carboxamide
• CAS: 74531-16-1
• 化学式: C₇H₁₀N₂O₂
• mdl: MFCD18833091
• 分子量: 154.169
• InChiKey: WKMJUXSOPIXZQM-UHFFFAOYSA-N

物化性质

• 沸点：
  313.3±30.0 °C(Predicted)
• 密度：
  1.125±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  46.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N,5-三甲基-1,2-恶唑-3-甲酰胺 在 dimethyl sulfide borane 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 6.33h， 生成 5-methyl-3-(N,N,N-trimethylammoniummethyl) isoxazole iodide
  参考文献：
  名称：

  Regioisomeric 3-, 4- and 5-aminomethyl isoxazoles: synthesis and muscarinic activity

  摘要：

  A series of 3-, 4- and 5-aminomethyl isoxazoles and isoxazoles with one or two additional methyl groups at the heterocycle were synthesized in order to investigate the structural requirements, ie heterocyclic moiety, regiochemistry and length of an aminoalkyl unit, for muscarinic activity. This was assayed on isolated rabbit vas deferens (M(1) receptor subtype) and isolated guinea-pig atrium (M(2) receptor subtype) and ileum (M(3) receptor subtype). The isoxazoles tested are one to three orders of magnitude less active than furane or oxadiazole derivatives, having similar structural characteristics except for the heterocycle. Thus, the differences in molecular point charges and charge distribution contribute to the muscarinic activity of these compounds more than small differences in molecular shape and conformational energies.

  DOI：

  10.1016/0223-5234(96)88303-6
• 作为产物：
  描述：

  乙酰丙酮酸甲酯 在 硫酸 、 盐酸羟胺 、 sodium acetate 作用下， 反应 5.0h， 生成 N,N,5-三甲基-1,2-恶唑-3-甲酰胺
  参考文献：
  名称：

  Regioisomeric 3-, 4- and 5-aminomethyl isoxazoles: synthesis and muscarinic activity

  摘要：

  A series of 3-, 4- and 5-aminomethyl isoxazoles and isoxazoles with one or two additional methyl groups at the heterocycle were synthesized in order to investigate the structural requirements, ie heterocyclic moiety, regiochemistry and length of an aminoalkyl unit, for muscarinic activity. This was assayed on isolated rabbit vas deferens (M(1) receptor subtype) and isolated guinea-pig atrium (M(2) receptor subtype) and ileum (M(3) receptor subtype). The isoxazoles tested are one to three orders of magnitude less active than furane or oxadiazole derivatives, having similar structural characteristics except for the heterocycle. Thus, the differences in molecular point charges and charge distribution contribute to the muscarinic activity of these compounds more than small differences in molecular shape and conformational energies.

  DOI：

  10.1016/0223-5234(96)88303-6

文献信息

• CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20120095040A1

  公开（公告）日：2012-04-19

  The invention relates to compounds of the general formula (I) where: R 2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy, or NR 8 R 9 group; m, n, o and p independently are a number from 0 to 3; A is a covalent bond, an oxygen atom, a C 1-6 -alkylene group or a —O—C 1-6 -alkylene group in which the end that is an oxygen atom is bonded to the R 1 group while the end that is an alkylene group is bonded to the carbon of the bicyclic compound; R 1 is an optionally substituted aryl or heteroaryl group; R 3 is a hydrogen or fluorine atom or a C 1-6 -alkyl or trifluoromethyl group; R 4 is an optionally substituted 5-membered heterocyclic compound; wherein the compounds can be in the state of a base or an acid addition salt. The invention can be used in therapeutics.

  该发明涉及一般式（I）的化合物，其中：R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基或NR8R9基团；m、n、o和p独立地是从0到3的数字；A是共价键、氧原子、C1-6-烷基烯基团或—O—C1-6-烷基烯基团，其中一个端是氧原子与R1基团结合，而另一个端是烷基烯基团与双环化合物的碳结合；R1是可选择取代的芳基或杂环芳基；R3是氢原子或氟原子或C1-6-烷基或三氟甲基基团；R4是可选择取代的5-成员杂环化合物；其中这些化合物可以处于碱性或酸性盐的状态。该发明可用于治疗学。
• CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20120015950A1

  公开（公告）日：2012-01-19

  Compound corresponding to general formula (I): in which R 2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy or NR 8 R 9 group; n is an integer equal to 1, 2 or 3 and m is an integer equal to 1 or 2; A is a covalent bond or a C 1-8 -alkylene group; R 1 is a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, naphthyl, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl group, this group being optionally substituted; R 3 is a hydrogen or fluorine atom, a C 1-6 -alkyl group or a tritluoromethyl group; R 4 is a group selected from furanyl, pyrrolyl, thienyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, imidazole, triazolyl, tetrazolyl, oxazolone, oxazolidinone, isoxazolone, isoxazolidinone, isothiazolone, isothiazolidinone, imidazolone, imidazolidinone, pyrazolone, pyrazolidinone, oxadiazolone, thiadiazolone and triazolone, this group being optionally substituted; in the form of a base or of an addition salt with an acid. Therapeutic use.

  与一般式(I)对应的化合物：其中R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基或NR8R9基团；n是等于1、2或3的整数，m是等于1或2的整数；A是共价键或C1-8-烷基烯基团；R1是苯基、吡啶基、吡啉基、嘧啶基、吡嗪基、三嗪基、萘基、喹啉基、异喹啉基、邻苯二嗪基、喹唑啉基、喹喜啉基、喹啉基、咔啉基或萘啉基团，该基团可选择性地被取代；R3是氢原子或氟原子、C1-6-烷基或三氟甲基基团；R4是从呋喃基、吡咯基、噻吩基、异噻唑基、噁唑基、异噁唑基、吡唑基、噁二唑基、噻二唑基、咪唑基、三唑基、四唑基、噁唑酮、噁唑烷酮、异噁唑酮、异噁唑烷酮、异噻唑酮、异噻唑烷酮、咪唑酮、咪唑烷酮、吡唑酮、吡唑烷酮、噁二唑酮、噻二唑酮和三唑酮中选择的基团，该基团可选择性地被取代；以盐酸形式或酸的加合盐形式存在。治疗用途。
• 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20120136026A1

  公开（公告）日：2012-05-31

  The invention relates to compounds of the general formula (I) where: R 2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy, or NR 8 R 9 group; m and p have a value of 1; n and o have the same value which is 0 or 1; A is a covalent bond or a C 1-8 -alkylene group; R 1 is an optionally substituted aryl or heteroaryl group; R 3 is a hydrogen or fluorine atom or a C 1-6 -alkyl group or a trifluoromethyl group; R 4 is an optionally substituted 5-membered heterocyclic compound; wherein the compounds can be in the state of a base or an acid addition salt. The present invention can be used in therapeutics.

  该发明涉及一般式（I）的化合物，其中：R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基或NR8R9基团；m和p的值为1；n和o具有相同的值，为0或1；A是共价键或C1-8-烷基烯基团；R1是可选择取代的芳基或杂环芳基团；R3是氢原子或氟原子或C1-6-烷基或三氟甲基基团；R4是可选择取代的5-成员杂环化合物；其中这些化合物可以处于碱态或酸盐加合物的状态。本发明可用于治疗学。
• Modulators of Muscarinic Receptors
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20130281476A1

  公开（公告）日：2013-10-24

  The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

  本发明涉及毒蕈碱受体调节剂。本发明还提供包含这种调节剂的组合物，并提供使用这种组合物治疗毒蕈碱受体介导疾病的方法。
• Micetich, Ronald G.; Shaw, Chia C.; Hall, Tse W., Heterocycles, 1985, vol. 23, # 3, p. 571 - 583
  作者：Micetich, Ronald G.、Shaw, Chia C.、Hall, Tse W.、Spevak, Paul、Fortier, Robert A.、et al.

  DOI：——

  日期：——